SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polack JM, MacIntyre I 1995 Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA 92: 29542958.
  • 2
    Kasten TP, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko TP, Settle SL, Currie MG, Nickols GA 1994 Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci USA 91: 35693573.
  • 3
    Chow JW, Fox SW, Lean JM, Chambers TJ 1998 Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res 13: 10391044.
  • 4
    van't Hof RJ, Ralston SH 1997 Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res 12: 17971804.
  • 5
    Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C 1996 Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 18: 301304.
  • 6
    Wimalawansa SJ, Chapa MT, Yallampalli C, Zhang R, Simmons DJ 1997 Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone 21: 275280.
  • 7
    Roselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK 1995 Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17B-estradiol and norethisterone acetate. Hypertension 25: 848853.
  • 8
    Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK 1997 Differential effects of hormone replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 82: 388394.
  • 9
    Ramsay B, Johnson MR, Leone AM, Steer PJ 1995 The effect of exogenous estrogen on nitric oxide production in women: A placebo controlled crossover study. Br J Obstet Gyneacol 102: 417419.
  • 10
    Kalinowski L, Dobrucki LW, Malinski T 2001 Nitric oxide as a second messenger in parathyroid hormone-related protein signaling. J Endocrinol 170: 433440.
  • 11
    Feelisch M 1993 Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J 14: 123132.
  • 12
    Thadani U 1997 Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther 10: 734742.
  • 13
    Jamal SA, Browner WS, Bauer DC, Cummings SR 1998 Intermittent use of nitrates increases bone mineral density: The study of osteoporotic fractures. J Bone Miner Res 13: 17551759.
  • 14
    Wimalawansa SJ 2000 Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: A human pilot clinical study. J Bone Miner Res 15: 22402244.
  • 15
    Anonymous 2002 Osteomark NTx Urine Product Description. Ostex International, Seattle, WA, USA, pp. 13.
  • 16
    Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring bone resorption: Quantitation of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7: 12511258.
  • 17
    Anonymous 2002 Metra BAP EIA kit. Quidel Corp., San Diego, CA, USA, pp. 16.
  • 18
    Gomez B, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41: 15601566.
  • 19
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 15861592.
  • 20
    Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH 2000 Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11: 467480.
  • 21
    Clowes JA, Eastell R 2002 Markers of bone turnover and laboratory evaluation of secondary osteoporosis. In: CummingsSR, CosmanF, JamalSA (eds.) Osteoporosis: An Evidenced-Based Guide to Prevention and Management. American College of Physicians, Philadelphia, PA, USA, pp. 5982.
  • 22
    Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87: 20602066.
  • 23
    Garnero P, Weichung JS, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79: 16931700.
  • 24
    Garnero P 2000 Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 (Suppl 6): S55S65.
  • 25
    Asirvatham S, Sebastian C, Thadani U 1998 Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf 19: 2344.